Shanghai, September 14, 2025 (Globe Newswire) – The 10th H2H Healthcare Ecosystem Conference, Fangzhou Inc. (“Fangzhou” or “Company”) (06086.hk) (06086.hk) has announced the release of “Xingshi”, a leader in AI-driven Internet healthcare solutions (06086.hk). It is designed to address the critical inefficiencies of chronic disease management by improving service efficiency, improving personalization, and allowing physicians to take advantage of the time available to them.
XS LLM integrates multimodal capabilities such as image and speech recognition, natural language processing, large-scale medical knowledge storage, and inference while achieving advanced performance benchmarks with medical AI. This core system supports five domain-specific intelligent agents: AI Knowledge Agent, AI Guidance Agent, AI Preconsult Agent, AI Doctor Assistant, and AI-Electronic Medical Record (EMR) Agent. Together, these agents create closed-loop service architectures that span the complete lifecycle of chronic disease management.
Built as “Core Digital Brain” on Fangzhou's platform, the model currently enhances five AI-enabled applications: AI Drug Finder, AI Health Manager, AI Doctor Assistant, AI Academic Assistant and AI-Driven Search. Each product addresses different clinical and patient-side use cases, allowing for real-time precision interventions across medication guidance, patient education, diagnostic assistance, and medical references.
Dr. Xie Fangmin, founder, chairman and CEO of Fangzhou, said: “This launch is not just a product milestone, it's a strategic inflection point. XSLLM embeds AI in every layer of chronic disease management, enabling accuracy, scale and accessibility in healthcare delivery.”
The launch reflects Fangzhou's stable AI build-out, from the introduction of the H2H (inter-hospital) digital ecosystem to the deployment of AI-powered customer service and knowledge base systems to now enterprise-grade medical LLM. By accelerating industrial adoption by China's “AI+” policy framework, Fangzhou has shown that XS LLM will strengthen its mission to anchor future R&D in chronic disease management applications and provide scalable and precision healthcare.
About Fangzhou Inc.
Fangzhou Inc. (06086.HK) is China's leading online chronic disease management platform, serving 52.8 million registered users and 229,000 doctors (as of June 30, 2025). The company specializes in providing tailored medical and AI-enabled precision medical solutions. For more information, please visit https://investors.jianke.com.
Media Contact
For further inquiries or interviews, please contact us as follows:
Xingwei Zhao Public Relations Representative Associate Director Email: pr@jianke.com
Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those expected due to a variety of factors. Readers are warned not to overrely rely on these statements
